Phase III randomized study of concurrent tretinoin and chemotherapy with or without arsenic trioxide (As2O3) as initial consolidation therapy followed by maintenance with intermittent tretinoin therapy versus intermittent tretinoin plus mercaptopurine and methotrexate for patients with untreated acute promyelocytic leukemia.